Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for Adc CRB-701 at ESMO Annual Congress.

Corbus Pharmaceuticals reported a Q2 basic EPS of -$1.44. The company initiated a multiple ascending dose portion of its Phase 1 study for its obesity treatment candidate, CRB-913. Corbus Pharmaceuticals was dropped from various Russell indices, including the Russell 3000 Index, Russell 2000 Index, and Russell 2500 Index.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) reported its Q2 2025 earnings on August 5, 2025, with a basic EPS of -$1.44, missing the consensus estimate by $0.08 [1]. The company initiated the multiple ascending dose (MAD) portion of its Phase 1 study for its obesity treatment candidate, CRB-913, with no treatment-related neuropsychiatric events reported in the single ascending dose (SAD) portion [3]. Despite the earnings miss, Corbus maintains a strong cash position of $116.6 million, sufficient to fund operations through Q2 2027 [3].

Corbus Pharmaceuticals was recently dropped from various Russell indices, including the Russell 3000 Index, Russell 2000 Index, and Russell 2500 Index [1]. The company's stock has experienced a significant year-to-date surge, increasing by 342%, but has seen target price reductions from various financial institutions in recent months [1].

The company's lead asset, CRB-701, a next-generation Nectin-4 targeting ADC for solid tumors, continues to show promising enrollment rates and will present Phase 1/2 dose expansion data at the European Society for Medical Oncology (ESMO) in October [3]. Additionally, CRB-601, an anti-αvβ8 integrin monoclonal antibody targeting TGFβ activation in the tumor microenvironment, continues dose escalation with data expected in Q4 2025 [3].

Analysts have mixed opinions on Corbus Pharmaceuticals' stock. B. Riley analyst M. Mamtani expects the company to post earnings of ($1.63) per share for the quarter, with a "Buy" rating and a $28.00 price target [1]. Royal Bank of Canada, HC Wainwright, and Oppenheimer have recently reduced their price objectives, while Lifesci Capital raised the stock to a "strong-buy" rating [1]. The consensus rating for Corbus Pharmaceuticals is currently "Moderate Buy" with an average target price of $49.38 [1].

Corbus Pharmaceuticals' stock traded up $0.03 on Friday, hitting $9.34, with a market capitalization of $114.32 million, a price-to-earnings ratio of -2.21, and a beta of 3.20 [1]. The company's 52-week low is $4.64, and the 52-week high is $61.89 [1].

References:
[1] https://www.marketbeat.com/instant-alerts/what-is-b-rileys-estimate-for-crbp-q2-earnings-2025-08-01/
[2] https://seekingalpha.com/news/4478364-corbus-pharmaceuticals-gaap-eps-of-1_44-misses-by-0_08
[3] https://www.stocktitan.net/news/CRBP/corbus-pharmaceuticals-reports-second-quarter-2025-financial-results-pmujisfw9o08.html